Knee Cartilage Repair Market is Projected to Surpass a Value of US$ 6.7 Bn by 2026

The global knee cartilage repair market was valued at approximately US$ 4.0 Bn in 2017. It is projected to expand at a cumulative annual growth rate (CAGR) of 6% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled ‘Knee Cartilage Repair Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ The report suggests that an increase in the number of bone and joint injuries, enhancement in technology, and rise in awareness about health care are expected to propel the knee cartilage repair market in the near future. Additionally, increase in concerns about sports injuries and arthritis-related diseases is anticipated to drive the global market.

North America and Europe are projected to dominate the global market, owing to an increase in orthopedic procedures, rise in incidence of obesity, and introduction of technologically advanced products in these regions. The market in Asia Pacific is projected to expand at a prominent CAGR between 2018 and 2026. This is due to increased spending on public health care systems, significant rise in the geriatric population, and increase in adoption of sports activities among the younger generation. The knee cartilage repair market in Latin America is likely to expand at a moderate growth rate during the forecast period.

The global knee cartilage repair market is projected to be driven by the rise in number of orthopedic surgeries and utilization of different implant materials during knee surgery streamlines the day to day work flow for differently abled or arthritis patients. Knee cartilage repair devices such as implants provide several features and benefits, such as patient easy mobility, which can be practiced by surgeons and physicians for the differently abled patients. Key players offering knee cartilage repair are developing value added features, such as biological or synthetics material features. These features help reduce the overall operating costs and improve effectiveness and efficiency of physiotherapy practiced on the knees.

Request to View Sample of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4481

Companies are focusing on the development of biological solutions for knee surgery-related issues. The market for biological or synthetic implant material is expanding significantly, worldwide, due to high success rate of the surgery, less post implantation infection, and high preference for the product by surgeons. Moreover, most innovative synthetic implants are not easily degraded in the body and provide efficiency during body mobility. BioPoly (material with its interpenetrated HA molecules), MaioRegen (Bio-mimetic, biointegratable and resorbable) are few examples of knee cartilage materials that save the operational time of physicians or surgeons and help improve the performance of patients post-surgery.

Arthroscopic chondroplasty involves the repair of a small area of damaged cartilage in the knee. During this procedure, the damaged tissue is removed, allowing healthy cartilage to grow in its place. Meniscal tears are the most common reason for arthroscopic chondroplasty. The damage caused through meniscal tears is trimmed and smoothened down through chondroplasty. Faster recovery time of arthroscopic chondroplasty, as compared to other traditional methods of open knee surgeries, is likely to drive the segment during the forecast period.

Technology-based knee cartilage repair are priced on a perpetual license model and are less expensive than other orthopedic surgeries. Arthroscopic chondroplasty enables users to practice low frequency clinical applications, allow healing of extreme pain in musculoskeletal structures, and provide assurance of 90% recovery by physicians. These factors are likely to propel the arthroscopic chondroplasty segment during the forecast period. It is preferred due to its low cost and outpatient procedure, which is used to repair a small area of damaged cartilage in the knee. Furthermore, arthroscopic chondroplasty based on technology facilitates pain relief and increases the range of motion and muscular strength among patients who have a knee injury.

The cell-based cartilage resurfacing segment is anticipated to expand at a higher CAGR during the forecast period. Factors attributed to the higher CAGR of the cell-based cartilage resurfacing segment include rise in the incidence of orthopedic surgeries, increase in the prevalence of damage articular cartilage and arthritis among the global population, and rise in demand for minimally invasive orthopedic surgeries from physicians and patients. Moreover, cell therapy and tissue engineering techniques are positively influencing orthopedic patients, which in turn is likely to fuel the demand for cell-based cartilage resurfacing application during the forecast period. Reimbursement and Medicare benefits available to patients for the treatment of knee arthritis and musculoskeletal disorders have contributed to the major share held by the cell-based cartilage resurfacing segment.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4481

The report also provides profiles of leading players operating in global knee cartilage repair market. DePuy Synthes, Zimmer Biomet, Stryker Corporation, Smith & Nephew plc, and B. Braun Melsungen AG are some leading players operating in the global knee cartilage repair market. They account for a significant share of the global market. Companies operating in the knee cartilage repair industry are aiming to increase their geographic presence by means of strategic acquisitions and collaborations with leading players in their respective domains and geographies.

In October 2014, Zimmer Biomet Holdings, Inc. acquired the business of Massachusetts-based ETEX Holdings, Inc., which offers bone void filler technologies for early stages of joint disease. The acquisition would enhance Zimmer's biologics portfolio of differentiated treatments through the addition of ETEX's Beta-bsm (injectable), CarriGen, EquivaBone (including DBM), and Gamma-bsm (putty) bone void filler products. Other prominent players operating in the global knee cartilage repair include Histogenics Corporation, ISTO Technologies, Inc., MEDIPOST Co. Ltd., Osiris Therapeutics, Inc., TiGenix NV, and Vericel Corporation.